HUITAI Biomedicine Co., Ltd, nestled in the vibrant city of Chengdu in southwestern China, is a clinical-stage biotech company. Our mission is to pioneer cutting-edge treatments for fibrotic diseases, harnessing the power of small polypeptide therapeutics known for their exceptional safety profiles.

We are dedicated to crafting breakthrough therapeutics aimed at combating the most severe and challenging fibrotic conditions affecting the lungs, liver, kidneys, and other vital organs. Each of our products is meticulously designed with a singular goal: to markedly enhance the benefit-risk ratio for patients, a critical factor in anti-fibrotic therapies.

Driven by a deeply personal connection to the cause, our company is proudly financed by its founders and executives, who have been directly impacted by pulmonary fibrosis, having lost beloved family members to this devastating disease. Their passion fuels our relentless pursuit of medical advancements that can transform lives.